ALGS Aligos Therapeutics

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024.

Please contact your Piper Sandler representative to schedule a one-on-one meeting.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

Company

Jordyn Tarazi

Vice President, Investor Relations & Corporate Communications

(650) 910-0427

Media

Michael Fitzhugh

LifeSci Communications

(628) 234-3889



EN
09/04/2024

Underlying

ALGSAligos Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aligos Therapeutics

 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Reports Recent Business Progress and Second Quart...

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory approvals across a number of countries, including the US, China...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on ...

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company...

July 30, 2025 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 2,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on July...

July 11, 2025 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of ...

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. “I am pleased to welcome Kieron to Aligos,” said Sushmita Chanda, PhD, DABT, Executive Vice Pr...

June 18, 2025 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on Jun...

June 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch